Generic Name and Formulations:
Streptozocin 1g/vial; pwd for IV inj or infusion after reconstitution/dilution; preservative-free.
Indications for ZANOSAR:
Symptomatic or progressive metastatic pancreatic islet cell cancer.
1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity.
Should be administered under the supervision of an experienced physician. Have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and toxicity. Mutagenic, tumorigenic, or carcinogenic.
Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see full labeling). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity.
GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?